Drug Profile
Allogeneic osteoblastic cell therapy - BioSenic
Alternative Names: ALLOB; ALLOB implantation; ALLOB-OP; Allogeneic-osteoblastic-cells-BioSenicLatest Information Update: 30 Jun 2023
Price :
$50
*
At a glance
- Originator Bone Therapeutics
- Developer BioSenic
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Fracture; Intervertebral disc degeneration
- Discontinued Osteoporosis
Most Recent Events
- 19 Jun 2023 A phase IIb trial in Fracture has been suspended in Belgium, Czech Republic, France, Germany, Hungary, Poland and Spain
- 03 Apr 2023 Bone Therapeutics completes enrolment in ALLOB-TF2 phase IIb trial for Fracture in Spain, Poland, Hungary, Germany, France, Czech Republic, Belgium (Intraosseous) (NCT04432389) (EudraCT2018-001054-96)
- 25 Oct 2022 Medsenic has been acquired by Bone Therapeutics and the later changed its name to BioSenic